On March 24, 2016, the Ministry of Science and Technology (China) announced the second dissemination of important national science and technology achievements. The newly published scientific and technological achievements include 130 items, mainly selected from the recent national "863" and "973" projects. Combined with the first publication on March 3, the Ministry of Science and Technology (China) will disseminate 113 scientific and technological achievements in the field of health this year, with medical devices accounting for 85 items. Wenzhou Medical University, Shenzhen Certainn Technology, and Beijing Eyebright have won 13 key projects in the field of ophthalmology. Also included are achievements of 8 projects commissioned to the China National Engineering Research Center of Ophthalmology and Optometry, Wenzhou Medical University, including an excimer laser refractive treatment device and RGP lens.

Latest News from Aier Eye Hospital Group

On March 28, 2016, Aier Eye Hospital released the financial report for 2015. According to the report, the sales amount was 3.166 billion yuan with a 31.79% increase from the previous year and the net profit was 428 million yuan with a 38.44% increase from the previous year. The net profit excluding non-recurring profit was 460 million yuan, which was 45.58% higher compared with the previous year. Excimer laser surgery sales were 840 million yuan with a 31.05% increase from the previous year, and optometry service sales were 638 million yuan with a 29.30% increase from the previous year. The most rapid sales increase was seen in cataract surgery, which sold 802 million yuan with a 39.56% increase from the previous year. As of the end of 2015, there were more than 100 facilities belonging to Aier Eye Hospital in 27 municipalities throughout China.

News from Grandhope Biotech Co.,Ltd.

After a 4-month suspension of transaction, Grandhope Biotech Co.,Ltd. announced on March 29, 2016 that it would acquire Sunny (Zhuhai) Pharmaceutical Co., Ltd., and declared the start of trading. There is also a possibility that the "优得清" artificial cornea developed by a subsidiary company will be put on the market in 2016. Grandhope Biotech paid 300 million yuan in cash and bought all shares of Sunny (Zhuhai) Pharmaceutical for a total purchase price of 600 million yuan.
Sunny assured shareholders that its net income excluding the non-recurring profit in 2016 and 2017 would be over 52 million yuan and 67.6 million yuan, respectively. Sunny's key business is the import and sale of IOL, and the company is the exclusive Chinese sales agent of IOL of the U.S. OII. Between 2012 and 2014, the volumes of IOL sales were 180,000, 190,000, and 240,000. In March 2016, Sunny was designated by ZEISS as a distributor in mainland China, and a supply agreement for LUCIA brand IOL products under ZEISS will be concluded sometime soon. The "优得清" artificial cornea is already under special review as an innovative medical device and is expected to be approved in the first half of 2016.